8 completed, 6 withdrawn, 1 active not recruiting, 1 terminated. 9 Phase 1, 6 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 6, Withdrawn 2, Active not recruiting 1 |
| Phase 3 | 6 | Withdrawn 3, Completed 2, Terminated 1 |
| Phase 2 | 4 | Withdrawn 2, Active not recruiting 1, Completed 1 |
Follow Clover Biopharmaceuticals AUS Pty: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity Study of SCB-1019T in Children low dose SCB-1019T, adjuvanted low dose SCB-1019T, high dose SCB-1019T - RSV Infection | Phase 1 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2025-10-01 | 2024-12-31 | |
| Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults SCB-1019T, SCB-1022, SCB-1033 - RSV Infection, Human Metapneumovirus Infection | Phase 1 / Phase 2 | Active not recruiting | Clover Biopharmaceuticals AUS Pty | 612 | 2025-06-18 | 2026-05-20 |
| First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults Candidate vaccine, SCB-1019, placebo, candidate vaccine, SCB-1019T - Respiratory Syncytial Virus Vaccination | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 160 | 2023-12-13 | 2025-06-06 |
| Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19, SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 - COVID-19 | Phase 3 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2023-10-01 | 2024-08-22 | |
| Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection, SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection - COVID-19 | Phase 3 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2023-08-17 | 2023-08-25 | |
| Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age Candidate vaccine, SCB-2019 - COVID-19 | Phase 2 / Phase 3 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2022-10-05 | 2023-03-24 | |
| Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults Candidate vaccine, SCB-2019, Comirnaty Vaccine, Vaxzevria Vaccine - COVID-19 | Phase 3 | Completed | Clover Biopharmaceuticals AUS Pty | 1831 | 2022-06-13 | 2023-08-24 |
| Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults Candidate vaccine, SCB-2020S, Candidate vaccine, SCB-2019, Squalene based adjuvant - COVID-19 | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 153 | 2022-05-30 | 2023-07-03 |
| Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration SCB-420, Aflibercept - Wet Age-related Macular Degeneration | Phase 1 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2022-04-01 | 2022-04-19 | |
| Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix, Placebo; 0.9% saline - COVID-19 | Phase 3 | Terminated | Clover Biopharmaceuticals AUS Pty | 1 | 2021-11-12 | 2023-03-24 |
| Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults candidate vaccine, SCB-2020S - COVID-19 | Phase 2 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2021-08-01 | 2021-09-10 | |
| A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Placebo; 0.9% saline, SCB-2019 vaccine - COVID-19 | Phase 2 / Phase 3 | Completed | Clover Biopharmaceuticals AUS Pty | 31454 | 2021-03-24 | 2023-06-29 |
| Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19. SCB-2019 - COVID-19 | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 137 | 2021-01-19 | 2022-02-11 |
| SCB-2019 as COVID-19 Vaccine SCB-2019, SCB-2019 with AS03 adjuvant, SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant - COVID-19 | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 166 | 2020-06-19 | 2022-02-18 |
| Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions SCB-313 - Malignant Pleural Effusions | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 5 | 2019-11-20 | 2022-02-02 |
| Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies SCB-313 - Peritoneal Malignancies | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 7 | 2018-06-18 | 2021-10-19 |
COVID-19 (10) · Respiratory Syncytial Virus Infections (2) · Paramyxoviridae Infections (1) · Pleural Effusion, Malignant (1)
SCB-2019 COVID-19 vaccine (9) · Sodium Chloride (3) · AS03 adjuvant (1) · Aluminum Hydroxide (1) · ChAdOx1 nCoV-19 (1) · Hepatitis A Vaccines (1) · Injections, Intramuscular (1) · aflibercept (1) · arexvy (1) · sinovac COVID-19 vaccine (1)
Australia (7) · Philippines (3) · Colombia (2) · South Africa (2) · Belgium (1) · Brazil (1) · Ukraine (1)
Christopher D Rook, MD (1) · Christopher Rook, MD (1) · Igor Smolenov, MD, PhD (1)
PMID 33524311, PMID 35065705, PMID 36433685, PMID 36781334, PMID 36868877, PMID 37226504, PMID 37439701, PMID 39218309